BIOLASE Schedule Of Investor Conferences For September 2021
BIOLASE, Inc. (NASDAQ: BIOL) announced its schedule for investor conferences in September 2021. Key events include one-on-one meetings at the Colliers 2021 Institutional Conference on September 9 and a formal presentation at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, with the presentation available on September 13 at 7:00 am ET. The company's leadership, including CEO John Beaver and VP of Finance Jennifer Bright, will participate in virtual meetings with institutional investors. More details can be found on BIOLASE's investor relations website.
- Scheduled participation in key investor conferences enhances visibility among institutional investors.
- CEO and VP of Finance will be directly engaging with potential investors, which may foster investor relations.
- None.
FOOTHILL RANCH, Calif., Sept. 8, 2021 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its schedule of investor conferences for September 2021:
Colliers 2021 Institutional Conference
Thursday, September 9 (one-on-one meetings only)
H.C. Wainwright 23rd Annual Global Investment Conference
Thursday, September 13-15th (formal presentation available September 13th at 7:00 am ET)
BIOLASE president and CEO John Beaver, and Vice President of Finance, Jennifer Bright will be hosting virtual one-on-one meetings with institutional investors at these conferences. For additional information or to schedule a virtual meeting with management, please contact your representative at the firms hosting the conferences, or BIOLASE's investor relations firm, EVC Group (contact info below).
To access a webcast of BIOLASE's presentation at the H.C. Wainwright conference, please visit the investor relations section of BIOLASE's website at www.biolase.com.
About BIOLASE, Inc.
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 271 patented and 40 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-schedule-of-investor-conferences-for-september-2021-301371708.html
SOURCE BIOLASE, Inc.
FAQ
What investor conferences is BIOLASE attending in September 2021?
When will BIOLASE's formal presentation be available at the H.C. Wainwright conference?
Who will represent BIOLASE at the September investor conferences?
How can I access BIOLASE's presentation at the investor conferences?
